高级搜索

TEL/AML1、BCR/ABL、E2A/PBX1、MLL/AF4阳性儿童急性淋巴细胞白血病的临床特点及预后

王颖超, 殷楚云, 李涛, 冯磊, 王春美, 盛光耀

王颖超, 殷楚云, 李涛, 冯磊, 王春美, 盛光耀. TEL/AML1、BCR/ABL、E2A/PBX1、MLL/AF4阳性儿童急性淋巴细胞白血病的临床特点及预后[J]. 肿瘤防治研究, 2012, 39(06): 687-690. DOI: 10.3971/j.issn.1000-8578.2012.06.018
引用本文: 王颖超, 殷楚云, 李涛, 冯磊, 王春美, 盛光耀. TEL/AML1、BCR/ABL、E2A/PBX1、MLL/AF4阳性儿童急性淋巴细胞白血病的临床特点及预后[J]. 肿瘤防治研究, 2012, 39(06): 687-690. DOI: 10.3971/j.issn.1000-8578.2012.06.018
shu
Wang Yingchao, Yin Chuyun, Li Tao, Feng Lei, Wang Chunmei, Sheng Guangyao. Clinical Features and Prognosis in Childhood Acute Plymphoblastic Leukemia with TEL/AML1,BCR/ABL,E2A/PBX1 and MLL/AF4 Positive[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 687-690. DOI: 10.3971/j.issn.1000-8578.2012.06.018
Citation: Wang Yingchao, Yin Chuyun, Li Tao, Feng Lei, Wang Chunmei, Sheng Guangyao. Clinical Features and Prognosis in Childhood Acute Plymphoblastic Leukemia with TEL/AML1,BCR/ABL,E2A/PBX1 and MLL/AF4 Positive[J]. Cancer Research on Prevention and Treatment, 2012, 39(06): 687-690. DOI: 10.3971/j.issn.1000-8578.2012.06.018
shu

TEL/AML1、BCR/ABL、E2A/PBX1、MLL/AF4阳性儿童急性淋巴细胞白血病的临床特点及预后

  • 1.450052 郑州，郑州大学第一附属医院儿科，2.血液病研究所

详细信息
    作者简介:

    王颖超（1970-），男，硕士，副教授，主要从事儿童血液或肿瘤疾病的研究

  • 中图分类号: R733.7

Clinical Features and Prognosis in Childhood Acute Plymphoblastic Leukemia with TEL/AML1,BCR/ABL,E2A/PBX1 and MLL/AF4 Positive

  • 1.Department of Pediatrics，The First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052，China，2.Department of Hematology

摘要

    摘要
  • 摘要: 目的 探讨儿童急性淋巴细胞白血病（ALL）TEL/AML1、BCR/ABL、E2A/PBX1、MLL/AF4四种融合基因的表达及其临床诊治意义。方法用实时荧光定量PCR(RQ-PCR)方法检测TEL/AML1、BCR/ABL（p190和p210两种亚型）、E2A/PBX1、MLL/AF4四种融合基因在312例ALL患儿中的表达情况，并总结融合基因阳性患儿的临床和生物学特点、治疗反应及预后情况。结果（1）融合基因阳性共120例，TEL/AML1阳性组72例(23.1%)，BCR/ABL阳性组22例(7.1%)，p190 16 例（5.1%）、p210 6例（1.9%），E2A/PBX1阳性组18例(5.8%)，MLL/AF4阳性组8例(2.6%)。（2）TEL/AML1阳性组诊断时WBC平均值为(18.02±6.45)×109/L，诱导化疗结束完全缓解率(CR)100%，随访期间无复发；BCR/ABL阳性组发病时年龄(9.40±3.55)岁，诱导化疗结束CR 81.8%，强化治疗末仍有6例融合基因未转阴，随访中有8例（36.3%）复发，8例死亡；E2A/PBX1阳性组全部按高危标准给予化疗，诱导化疗结束CR 88.9%，强化治疗期末仍有3例基因微量表达，随访中2例复发；MLL/AF4阳性组发病时WBC(38.41±9.30)×109/L，强化治疗期末仍有2例基因呈阳性，随访中均复发死亡。结论融合基因可作为ALL危险度分层、监测微小残留病、判断预后的重要指标之一。

     

    Abstract: Objective To explore the expression and clinical significance of TEL/AML1,BCR/ABL，E2A/PBX1 and MLL/AF4 fusion gene in childhood acute lymphoblastic leukemia(ALL). Methods Bone marrow samples were collected from 312 children with newly diagnosed ALL，and E2A/PBX1，BCR/ABLp190(e1a2)and p210(b2a3,b3a2) isoforms，TEL/AML1 and MLL/AF4 fusion gene were detected by RQ-PCR.Meanwhile，Clinico-biological characteristic，therapeutic response and outcome were retrospectively analyzed. Results （1） The fusion genes were positive in 120 ALL children.72 cases(23.1%) expressed TEL/AML1，22 cases(7.1%) expressed BCR-ABL(including 16 cases(5.1%)p190 and 6 cases(1.9%) p210，18 cases(5.8%) expressed E2A/PBX1 and 8 cases(2.6%) expressed MLL/AF4).（2） In TEL/AML1 positive children，the leukocyte count was(18.02±6.45)×109/L with a 100% complete remission(CR) rate and none relapsed during follow-up.In BCR/ABL positive children，the mean age was(9.40±3.55) years old with 81.8% CR rate.6 cases still expressed the fusion gene at the end of intensive treatment.8 children relapsed and 8 children died during follow-up.In E2A/PBX1 positive children，all of them were given chemotherapy according to high risk standard.The CR rate was 88.9%.Three cases expressed micro-content fusion gene at the end of intensive treatment.2 cases relapsed during follow-up.In MLL/AF4 positive children，the leukocyte count was(41.53±9.46)×109/L.2 cases still expressed the fusion gene at the end of intensive treatment，and both of them relapsed and died. Conclusion Fusion genes are important indexes for risk stratification,MRD monitoring and prognosis estimation in children with ALL.

     

    • HTML全文
    • 参考文献(15)
  • [1] The Subspecialty Group of Hematology Diseases.The society of pediatrics,Chinese MedicalAssociation.The Editorial Board.Chinese Journal of Pediatrics.Suggestion of diagnosis and treatmentof acute lymphoblastic leukemia in childhood(The 3rd revised version)[J].Zhonghua Er Ke ZaZhi,2006,44(5):392-5.[中华医学会儿科学分会血液学组.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-5.]
    [2] Szczepański T，Orfo A，van der Velden VH，et al.Minimal residual disease in leukaemiapatients[J].Lancet Oncol，2001,2(7):409-17.
    [3] Jiménez-Morales S，Miranda-Peralta E，Saldaa-Alvarez Y,et al.BCR-ABL，ETV6-RUNX1 and E2A-PBX1:prevalence of the most common acute lymphoblastic leukemia fusion genes in Mexican patients[J].Leuk Res，2008,32(10):1518-22.
    [4] Chowdhury T，Brady HJ.Insights from clinical studies into the role of the MLL gene in infantand childhood leukemia[J].Blood Cells Mol Dis,2008,40(2):192-9.
    [5] Balgobind BV，Raimondi SC，Harbott J，et al.Novel prognostic subgroups in childhood 11q23/MLLrearranged acute myeloid leukemia:results of an international retrospective study[J].Blood,2009,114(12):2489-96.
    [6] Bardini M，Galbiati M，Lettieri A,et al.Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients[J].Leukemia，2011,25(1):175-8.
    [7] Na IK，Kreuzer KA，Lupberger J，et al.Quantitative RT-PCR of Wilms tumor gene transcripts(WT1)for the molecular monitoring of patients with accelerated phase bcr/abl+CML[J].Leuk Res,2005,29(3):343-5.
    [8] Pui CH,Relling MV,Downing JR.Acute lymphoblastic leukemia[J].N Engl J Med,2004,350(15):1535-48.
    [9] Bartley PA，Ross DM，Latham S,et al.Sensitive detection and quantification of minimal residualdisease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA[J].Int J LabHematol,2010,32(6 Pt 1):e222-8.
    [10] Lin D,Liu SH,Zhu XF,et al.Study of the childhood acute lymphoblastic leukemia with t(12;21)[J].Zhonghua Xue Ye Xue Za Zhi,2004,25(1):17-21.[林冬，刘世和，竺晓凡，等.t(12；21）儿童急性淋巴细胞白血病的研究[J].中华血液学杂志，2004,25(1):17-21.]
    [11] Loh ML，Goldwasser MA，Silverman LB，et al.Prospective analysis of TEL/AML1-positive patientstreated on Dana-Farber Cancer Institute Consortium Protocol 95-01[J].Blood,2006,107(11):4508-13.
    [12] Foa R,Vitale A,Mancini M,et al.E2A-PBXl fusion in adult acute lymphoblasticleukemia:biological and clinical features[J].Br J Hematol,2003，120(3):484-7.
    [13] Pui CH，Sandlund JT，Pei D，et al.Results of therapy for acute lymphoblastic leukemia in blackand white children[J].JAMA,2003,290(15):2001-7.
    [14] Stams WA，Beverloo HB，den Boer ML，et al.Incidence of additional genetic changes in the TELand AML1 genes in DCOG and COALL-treated t(12;21) positive pediatric ALL，and their relation withdrug sensitivity and clinical outcome [J].Leukemia,2006，20(3):410-6.
    [15] Dong M，Blobe GC.Role of transforming growth factor-β in hematologic malignancies [J].Blood，2006，107(12):4589-96.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数:  6268
  • HTML全文浏览量:  18
  • PDF下载量:  847
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-07-31
  • 修回日期:  2011-11-17
  • 刊出日期:  2012-06-24

目录

摘要
HTML全文
    参考文献(15)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    下载中心

    友情链接

    联系我们

    地址：武汉市洪山区卓刀泉南路116号（430079）

    电话：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    邮件订阅 RSS
    总访问量：11748884 今日访问：16617

    版权所有 © 《肿瘤防治研究》编辑部 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    本系统由北京仁和汇智信息技术有限公司开发  百度统计

    x 关闭 永久关闭